Financial Performance - Karyopharm Therapeutics reported quarterly losses of $2.77 per share, which was better than the analyst consensus estimate of losses of $4.16 per share [1] - The company reported quarterly sales of $30.02 million, missing the analyst consensus estimate of $35.24 million [1] Clinical Trial Update - The Phase 3 SENTRY trial in patients with JAKi-naïve myelofibrosis has passed its pre-specified futility analysis and continues as planned without modifications [2] - New data in hard-to-treat myelofibrosis patients showed spleen volume reduction, symptom improvement, hemoglobin stabilization, and evidence of disease modification with selinexor monotherapy [2] Sales Guidance and Market Reaction - Karyopharm affirmed FY2025 sales guidance of $140.00 million to $155.00 million, compared to market estimates of $149.32 million [3] - Following the earnings announcement, Karyopharm shares fell 15.6% to trade at $5.17 [3] Analyst Ratings and Price Targets - Baird analyst Michael Ulz maintained an Outperform rating and lowered the price target from $54 to $42 [8] - Barclays analyst Peter Lawson maintained an Overweight rating and raised the price target from $5 to $10 [8] - RBC Capital analyst Brian Abrahams maintained an Outperform rating and lowered the price target from $34 to $33 [8]

TransMedics Group (TMDX) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Company Participants Laine Morgan - Associate Vice PresidentWaleed Hassanein - Founder, President, CEO & DirectorGerardo Hernandez - Chief Financial OfficerAllen Gong - Vice PresidentWilliam Plovanic - Managing Director - Equity ResearchJustin Wang - Equity Research AssociateChris Pasquale - Partner - Medical Devices & SuppliesSuraj Kalia - Managing DirectorJosh Jennings - Managing Director Conference Call Participants Samantha Munoz - ...

据华尔街日报：美国食品药品监督管理局（FDA）要求疫苗生产商诺瓦瓦克完成新一轮临床试验，以推 进延迟推出的新冠病毒疫苗。 ...

齐鲁晚报.齐鲁壹点孙淑玉通讯员徐明华 2025年2月18日至2月19日，山东省药品监督管理局委托食品药品审评查验中心对烟台市中心血站进行现 场监督检查。检查专家通过听取汇报、现场访谈、查看文件资料和场所设施设备等形式，对机构、伦理 和备案专业科室进行详细检查和指导。检查组对烟台市中心血站医疗器械临床试验管理机构的建设管理 工作给予了充分肯定，对现场检查中发现的不足之处进行指导，并提出专业性的整改意见和建议，烟台 市中心血站按照要求完成整改。近日，经山东省药品监督管理局认定，烟台市中心血站医疗器械临床试 验机构综合评定结论为符合要求，顺利通过国家医疗器械临床试验管理机构备案评审。 此次医疗器械备案成功，标志着烟台市中心血站正式跻身国家级医学研究创新平台行列，开启了从"血 液安全守护者"向"医学科研创新者"跨越式发展的新篇章。烟台市中心血站将以此为契机，严格遵守相 关法律法规，持续推进机构建设，搭建连接基础输血研究、临床应用和产业转化的桥梁，以科技创新赋 能血液安全，以严谨求实守护生命希望，为健康烟台建设贡献血站力量。 近日，从烟台市卫生健康委获悉，烟台市中心血站成功通过国家医疗器械临床试验机构备案(备案号： 械 ...

Cognition Therapeutics, Inc (NASDAQ:CGTX) Q4 2024 Results Conference Call March 20, 2025 8:00 AM ET Company Participants Mike Moyer - LifeSci Advisors Lisa Ricciardi - Chief Executive Officer John Doyle - Chief Financial Officer Anthony Caggiano - Chief Medical Officer, Head of R&D Conference Call Participants Mayank Mamtani - B. Riley Securities Daniil Gataulin - Chardan Operator Greetings, and welcome to the Cognition Therapeutics Fourth Quarter and Full Year 2024 Earnings Call. [Operator Instructions] As ...